Mediator complex subunit 1 architects a tumorigenic Treg cell program independent of inflammation.

While immunotherapy has revolutionized cancer treatment, its safety has been hampered by immunotherapy-related adverse events. Unexpectedly, we show that Mediator complex subunit 1 (MED1) is required for T regulatory (Treg) cell function specifically in the tumor microenvironment. Treg cell-specific MED1 deletion does not predispose mice to autoimmunity or excessive inflammation. In contrast, MED1 is required for Treg cell promotion of tumor growth because MED1 is required for the terminal differentiation of effector Treg cells in the tumor. Suppression of these terminally differentiated Treg cells is sufficient for eliciting antitumor immunity. Both human and murine Treg cells experience divergent paths of differentiation in tumors and matched tissues with non-malignant inflammation. Collectively, we identify a pathway promoting the differentiation of a Treg cell effector subset specific to tumors and demonstrate that suppression of a subset of Treg cells is sufficient for promoting antitumor immunity in the absence of autoimmune consequences. Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Citation

Shuvam M Chaudhuri, Samuel E Weinberg, Dongmei Wang, Lenore K Yalom, Elena Montauti, Radhika Iyer, Amy Y Tang, Manuel A Torres Acosta, Jian Shen, Nikita L Mani, Shengnan Wang, Kun Liu, Weiyuan Lu, Triet M Bui, Laura D Manzanares, Zeinab Dehghani, Ching Man Wai, Beixue Gao, Juncheng Wei, Feng Yue, Weiguo Cui, Benjamin D Singer, Ronen Sumagin, Yana Zhang, Deyu Fang. Mediator complex subunit 1 architects a tumorigenic Treg cell program independent of inflammation. Cell reports. Medicine. 2024 Mar 19;5(3):101441

Mesh Tags

Substances

PMID: 38428427

search → result